Teladoc Health, Inc. $TDOC Stock Holdings Lifted by Quantinno Capital Management LP

Quantinno Capital Management LP grew its stake in shares of Teladoc Health, Inc. (NYSE:TDOC) by 128.0% in the first quarter, according to its most recent filing with the SEC. The fund owned 2,621,378 shares of the health services provider’s stock after acquiring an additional 1,471,631 shares during the period. Quantinno Capital Management LP’s holdings in Teladoc Health were worth $14,287,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. SummitTX Capital L.P. acquired a new position in shares of Teladoc Health in the 1st quarter worth $339,000. Renaissance Technologies LLC lifted its holdings in shares of Teladoc Health by 1.3% during the first quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider’s stock valued at $44,066,000 after purchasing an additional 107,400 shares during the last quarter. Pale Fire Capital SE lifted its holdings in shares of Teladoc Health by 74.8% during the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock valued at $18,522,000 after purchasing an additional 1,454,288 shares during the last quarter. Levin Capital Strategies L.P. acquired a new position in shares of Teladoc Health in the 1st quarter valued at $82,000. Finally, First Trust Advisors LP boosted its position in shares of Teladoc Health by 63.2% in the 1st quarter. First Trust Advisors LP now owns 350,017 shares of the health services provider’s stock valued at $1,908,000 after purchasing an additional 135,520 shares during the period. 76.82% of the stock is owned by institutional investors.

More Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported a second-quarter adjusted loss of $0.21 per share, better than the consensus estimate of a $0.24 loss. Strength in Integrated Care and international operations helped offset weakness in BetterHelp. Teladoc Health Q2 Earnings Beat Estimates on Integrated Care Strength
• Positive Sentiment: Management’s cost controls and efficiency measures appear to be narrowing losses over the first half of 2026, while some investors see the stock as potentially undervalued following the selloff. Teladoc Health Could Be Undervalued
• Neutral Sentiment: Canaccord Genuity maintained a Buy rating but lowered its price target from $11 to $10. Separately, traders purchased about 15,650 call options, roughly 30% above typical volume, suggesting some speculative bullish positioning but not necessarily a change in fundamentals.
• Negative Sentiment: Second-quarter revenue fell 4% year over year to $606.9 million, missing analysts’ $615.4 million estimate. Teladoc also posted a $38.9 million net loss, or $0.21 per share, compared with a $0.19 loss in the year-earlier quarter. Teladoc Tumbles on Revenue Forecast Cut
• Negative Sentiment: The key pressure is BetterHelp, where shifting demand reduced cash-pay revenue. After a 12% annual decline in the latest quarter, the company indicated the division could decline as much as 19% for the full year, undermining expectations for a recovery. Teladoc Health Investigation Notice
• Negative Sentiment: Teladoc’s third-quarter revenue outlook of approximately $589 million was below expectations, and the company lowered its full-year revenue forecast. The weaker outlook outweighed the adjusted earnings beat and caused analysts and investors to reset expectations for growth and profitability. Teladoc Stock Plummets on Revenue Miss and Lowered Outlook
• Negative Sentiment: Levi & Korsinsky announced a pending investigation into Teladoc, adding potential legal and reputational risk to an already weak earnings narrative. The investigation notice does not establish wrongdoing, but it may further weigh on sentiment.

Insider Buying and Selling at Teladoc Health

In related news, insider Carlos Nueno sold 6,196 shares of the company’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $47,275.48. Following the completion of the sale, the insider directly owned 57,671 shares in the company, valued at approximately $440,029.73. This represents a 9.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $145,977.16. Following the transaction, the chief executive officer directly owned 389,894 shares in the company, valued at $2,974,891.22. The trade was a 4.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 39,195 shares of company stock worth $299,058 in the last 90 days. 0.70% of the stock is currently owned by company insiders.

Teladoc Health Stock Performance

Shares of NYSE TDOC opened at $6.71 on Monday. The business has a 50 day simple moving average of $8.21 and a 200 day simple moving average of $6.54. Teladoc Health, Inc. has a 52 week low of $4.40 and a 52 week high of $9.89. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -6.78 and a beta of 2.10.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The firm had revenue of $606.93 million during the quarter, compared to analysts’ expectations of $615.44 million. During the same period in the previous year, the company earned ($0.19) earnings per share. The company’s revenue was down 4.0% compared to the same quarter last year. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. On average, analysts predict that Teladoc Health, Inc. will post -0.88 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Bank of America boosted their price objective on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Weiss Ratings raised shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Canaccord Genuity Group cut their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Citigroup raised their price objective on shares of Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 5th. Five investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $7.50.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.